http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021228888-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a35cd89af091fdfcce85acc33851df1c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2021-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f38c35a217da792d82a4a69fef9a9c0 |
| publicationDate | 2021-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021228888-A1 |
| titleOfInvention | Biomarkers for hyperprogressive disease and therapy response after immunotherapy |
| abstract | The invention relates to the field of diagnostics to guide cancer immunotherapy. More specifically, the invention provides a method for determining the likelihood of hyperprogression and/or progressive disease of cancer cells in response to immunotherapy, such as immune checkpoint inhibitor treatment. Furthermore, the invention also provides a method for determining the likelihood of a positive response to immunotherapy, such as immune checkpoint inhibitor treatment. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114694745-A |
| priorityDate | 2020-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.